# A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults

> **NCT03357263** · PHASE1 · COMPLETED · sponsor: **Green Cross Corporation** · enrollment: 40 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** GC3114
- **BIOLOGICAL:** GCFLU Quadrivalent

## Key facts

- **NCT ID:** NCT03357263
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-20
- **Primary completion:** 2017-12-22
- **Final completion:** 2017-12-22
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03357263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03357263, "A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03357263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*